Stockscreener 앱 받기
0.5616
2.89%
-0.0167
시간 외 거래:
.56
-0.0016
-0.28%
전일 마감가:
$0.5783
열려 있는:
$0.575
하루 거래량:
3.05M
Relative Volume:
0.59
시가총액:
$169.44M
수익:
$52.29M
순이익/손실:
$-134.84M
주가수익비율:
-0.7488
EPS:
-0.75
순현금흐름:
$-117.11M
1주 성능:
-4.89%
1개월 성능:
-17.76%
6개월 성능:
-22.89%
1년 성능:
-67.72%
1일 변동 폭
$0.5538
$0.5977
1주일 범위
$0.5538
$0.6219
52주 변동 폭
$0.4111
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
명칭
Sangamo Therapeutics Inc
전화
(510) 970-6000
주소
501 CANAL BLVD., RICHMOND, CA
SGMO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.5616 | 174.48M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-13 | 업그레이드 | Truist | Hold → Buy |
| 2024-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-02-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
| 2021-01-07 | 재개 | Guggenheim | Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-12-16 | 재개 | H.C. Wainwright | Buy |
| 2020-09-08 | 개시 | BofA Securities | Buy |
| 2020-07-07 | 개시 | SunTrust | Buy |
| 2019-08-26 | 개시 | H.C. Wainwright | Buy |
| 2018-11-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2018-10-10 | 개시 | Guggenheim | Buy |
| 2018-06-20 | 개시 | BofA/Merrill | Buy |
| 2017-11-15 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2016-11-01 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-10-19 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-10-23 | 재개 | Jefferies | Buy |
| 2013-05-03 | 개시 | BioLogic Equity Research | Sell |
| 2011-02-23 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-07-29 | 재확인 | Wedbush | Outperform |
| 2009-10-19 | 개시 | Brean Murray | Sell |
| 2009-10-07 | 재확인 | Leerink Swann | Outperform |
| 2009-08-25 | 재확인 | JMP Securities | Mkt Outperform |
모두보기
Sangamo Therapeutics Inc 주식(SGMO)의 최신 뉴스
Sangamo Therapeutics Inc expected to post breakeven results a shareEarnings Preview - TradingView
Will Sangamo Therapeutics Inc. stock outperform Nasdaq indexJuly 2025 Movers & Safe Capital Investment Plans - newser.com
Tick level data insight on Sangamo Therapeutics Inc. volatility2025 Market WrapUp & Precise Buy Zone Identification - newser.com
Can Sangamo Therapeutics Inc. stock outperform in 2025 bull marketTrade Risk Summary & Reliable Entry Point Trade Alerts - newser.com
Published on: 2025-11-04 04:55:19 - newser.com
Why analysts recommend Sangamo Therapeutics Inc. (GBY) stock2025 Winners & Losers & Daily Growth Stock Investment Tips - newser.com
How buybacks impact Sangamo Therapeutics Inc. stock value2025 Earnings Impact & Low Volatility Stock Recommendations - newser.com
How hedge fund analytics apply to Sangamo Therapeutics Inc. stock2025 Retail Activity & Fast Gain Swing Trade Alerts - newser.com
Using AI based signals to follow Sangamo Therapeutics Inc.Earnings Overview Summary & Expert Approved Momentum Ideas - newser.com
What analysts say about Sangamo Therapeutics Inc GBY stockMarket Entry Points & Free Extraordinary Earning Power - earlytimes.in
Real time pattern detection on Sangamo Therapeutics Inc. stockTreasury Yields & Long-Term Growth Plans - newser.com
Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call - Zenopa
Is Sangamo Therapeutics Inc. stock in correction or buying zoneJuly 2025 Short Interest & AI Enhanced Execution Alerts - newser.com
Is Sangamo Therapeutics Inc. stock a safe haven asset2025 Earnings Surprises & Entry Point Strategy Guides - newser.com
How Sangamo Therapeutics Inc. stock reacts to bond yieldsEarnings Risk Report & Risk Managed Investment Entry Signals - newser.com
What analyst consensus says on Sangamo Therapeutics Inc. stock2025 Pullback Review & Verified Momentum Watchlists - newser.com
Detecting price anomalies in Sangamo Therapeutics Inc. with AIJuly 2025 Decliners & Free Daily Entry Point Trade Alerts - newser.com
What machine learning models say about Sangamo Therapeutics Inc.Profit Target & AI Based Trade Execution Alerts - newser.com
Sangamo Therapeutics Inc. stock chart pattern explainedMarket Activity Summary & Daily Entry Point Trade Alerts - newser.com
How Sangamo Therapeutics Inc. (GBY) stock reacts to monetary easingJuly 2025 Outlook & Stepwise Entry/Exit Trade Alerts - newser.com
Why retail investors favor Sangamo Therapeutics Inc. stockJuly 2025 Chart Watch & Reliable Momentum Entry Alerts - newser.com
What analysts say about Sangamo Therapeutics Inc stockEarnings Per Share Trends & Big Returns, Small Investment – Learn How - earlytimes.in
Sangamo Therapeutics (NASDAQ: SGMO) to host earnings call Nov. 6 at 8:30 a.m. ET - Stock Titan
We're Hopeful That Sangamo Therapeutics (NASDAQ:SGMO) Will Use Its Cash Wisely - Yahoo Finance
Published on: 2025-10-29 21:25:18 - newser.com
Sangamo Biosciences Granted Nasdaq Compliance Extension - TipRanks
Sangamo Therapeutics Inc (SGMO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):